PLYX today
$1.80-$0.08 (-4.49%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minLeaning Bearish
5 minConsolidating
Daily trend turns up above $1.99
Key levels
Resistance$1.99
Resistance$1.83
Support$1.69
Latest news & SEC filings
EarningsPolaryx Therapeutics Posts Q3 2026 Financials
EarningsPolaryx Therapeutics posts wider quarterly loss than analysts expected
ProductPolaryx Therapeutics opens first site for SOTERIA Phase 2 trial of PLX-200
All PLYX news →About Polaryx Therapeutics
Polaryx Therapeutics develops treatments for uncommon inherited metabolic diseases that strike young children, known as lysosomal storage disorders. Its main drug candidate, PLX-200, is taken by mouth and is being tested in a mid-stage study covering four conditions: two forms of Batten disease, Krabbe disease, and Sandhoff disease. The company also has earlier research programs using small molecules and gene-based medicine. It focuses on patients across North America, Europe, and other parts of the world.
Based on the company's 10-K filed Mar 24, 2026.
Nasdaq · Healthcare
Polaryx Therapeutics, Inc. (PLYX)
What Is the Price Target for PLYX?
SEPT Low Target
$6.00
SEPT Mid Target
$6.50
SEPT High Target
$7.00
Analyst Consensus
$6.50
Is PLYX a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for PLYX.
Start Free Trial →Is PLYX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$6.50
12
Moat Score
NONE
2/9
Piotroski Score
53.3
Altman Z-Score
What Is Smart Money Doing with PLYX?
Insider Signal
NEUTRAL
1 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Yang Alex Keun Mo | director officer 10% owner | Buy | 88,453 | $360K | May 27, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →PLYX Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
77.53%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for PLYX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for PLYX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:49:13 | $1.82 | 1,373 | $$2K | SELL |
| 09:02:33 | $1.79 | 1,000 | $$2K | SELL |
| 16:50:20 | $1.92 | 1,000 | $$2K | SELL |
| 15:25:12 | $1.90 | 1,850 | $$4K | SELL |
| 19:08:49 | $1.92 | 1,297 | $$2K | BUY |
5 dark pool trades shown · $$12K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Polaryx Therapeutics, Inc. (PLYX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →PLYX — frequently asked questions
What is PLYX stock price today?
Polaryx Therapeutics, Inc. (PLYX) is at $1.80, down 4.49% (-$0.08) at the Nov 13, 2026 close.
Why is PLYX stock moving today?
Latest PLYX news — Nov 13, 2026: Polaryx Therapeutics Posts Q3 2026 Financials · Nov 12, 2026: Polaryx Therapeutics posts wider quarterly loss than analysts expected
What is the PLYX price target?
The average analyst price target for PLYX is $6.50, ranging from $6 to $7, based on 4 analysts. Latest: Polaryx Therapeutics upgrade on Aug 13, 2026.
What do analysts rate PLYX?
Analyst ratings for PLYX: 0 Buy, 4 Hold, 0 Sell — consensus Hold.
Did PLYX beat earnings?
PLYX last reported on Aug 13, 2026: EPS -$0.03 vs -$0.04 expected — a beat of 14.3%.
What are PLYX support and resistance levels?
Support: $1.69. Resistance: $1.83, $1.99, $2.15.
What are insiders doing with PLYX?
Insider activity: NEUTRAL, 1 buys and 0 sells in the last 90 days.
What is the latest news on PLYX?
Nov 13, 2026: Polaryx Therapeutics Posts Q3 2026 Financials · Nov 12, 2026: Polaryx Therapeutics posts wider quarterly loss than analysts expected · Nov 9, 2026: Polaryx Therapeutics opens first site for SOTERIA Phase 2 trial of PLX-200